Summary

The presurgical window of opportunity trial (WOT) MIPRA provides evidence that neoadjuvant treatment with the progesterone receptor (PR) antagonist mifepristone (RU486) may benefit patients with estrogen receptor–positive (ER+) breast cancer characterized by a high ratio of PR-A versus PR-B isoform (>1.5), suggesting that PR may be targeted in a subset of patients.

See related article by Elía et al., p. 866

©2022 American Association for Cancer Research
2022
American Association for Cancer Research
You do not currently have access to this content.